Bone matters in lung cancer.

Ann Oncol · 2012 · PMC3425370 · PMID 22357445

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

showed a trendP = 0.14not close (p > 0.1)

Denosumab also showed a trend of delayed time to first and subsequent SREs over zoledronic acid [rate ratio = 0.90; 95% CI 0.77–1.04; P = 0.14 (superiority)].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.